Beta-blocker and calcium-channel blocker therapy in patients with cardiovascular pathologies during post-COVID period
A. G. Arutyunov,
G. P. Arutyunov,
E. I. Tarlovskaya,
T. I. Batluk,
R. A. Bashkinov,
E. D. Gordeychuk,
A. N. Ermilova,
A. V. Klimova,
T. V. Kryukova,
E. S. Melnikov,
M. A. Trubnikova https://doi.org/10.51793/OS.2021.24.12.007
Abstract
Early in 2020, the infection caused by SARS-CoV-2 emerged and caused the COVID-19 pandemic. For a long time, management of patients with the acute novel coronavirus infection was of primary importance. With accumulation of clinical information and data on the causative agents of novel coronavirus infection it became obvious that the COVID-19 consequences and post-hospital follow-up of patients are important as well. Due to the direct and mediated cardiac toxicity of SARS-CoV-2 virus, cardiovascular patients are at high risk at any stage of the disease. Therefore, one of the priorities for healthcare professionals is development of the ways to improve the quality and prognosis of life for cardiovascular patients in the post-COVID period. The article discusses large-scale studies including the data from the International Register «Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult Patients» (AСTIV-SARS-CoV-2), as regards drug therapy of cardiovascular patients with a focus on beta-blockers and calcium-channel blockers. In mentioned publications, beta-blocker therapy demonstrated favourable impact on the novel coronavirus infection severity in cardiovascular patients, reduction in mortality rates during the hospital and post-hospital periods. Data on the use of calcium-channel blockers have been studied to a lesser extent; however, calcium-channel blockers are thought to be one of the most commonly prescribed groups in the therapy of patients with persistent complaints of high blood pressure at the post-hospital period. A study of the impact of some categories of antihypertensives on the outcome for cardiovascular patients with COVID-19 is warranted.
About the Authors
A. G. Arutyunov
Eurasian Association of Therapists; Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
Россия
Россия
Aleksandr G. Arutyunov - Dr. of Sci. (Med.), Associate Professor, Secretary General of Eurasian Association of Therapists; Professor of the Department of Internal Medicine and General Physiotherapy at the Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation;
18A Milyutinsky lane, Moscow, 101000; 1 Ostrovityanova str., Moscow, 117997.
G. P. Arutyunov
Eurasian Association of Therapists; Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
Россия
Россия
Grigory P. Arutyunov - Dr. of Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences, President of the Eurasian Association of Therapists; Head of the Department of Internal Medicine and General Physiotherapy at the Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation;
18A Milyutinsky lane, Moscow, 101000; 1 Ostrovityanova str., Moscow, 117997.
E. I. Tarlovskaya
Eurasian Association of Therapists; Volga Research Medical University of the Ministry of Health of the Russian Federation
Россия
Россия
Еkaterina I. Tarlovskaya - Dr. of Sci. (Med.), Professor, Head of the Department of therapy and cardiology at the Volga Research Medical University of the Ministry of Health of the Russian Federation; Chairperson of Eurasian Association of Therapists branch in Nizhny Novgorod.
10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005; 18A Milyutinsky lane, Moscow, 101000.
T. I. Batluk
Eurasian Association of Therapists; Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
Россия
Россия
Tatiana I. Batluk - MD, Assistant Lecturer, Department of Internal Medicine Propaedeutics, Pediatric Faculty at the Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation; Medical adviser of Eurasian Association of Therapists.
1 Ostrovityanova str., Moscow, 117997; 18A Milyutinsky lane, Moscow, 101000.
R. A. Bashkinov
Eurasian Association of Therapists; North-Western State Medical University named after I.I. Mechnikov of the Ministry of Health of the Russian Federation
Россия
Россия
Roman A. Bashkinov - Medical adviser of Eurasian Association of Therapists; PhD student of the department of therapy, rheumatology, examination of temporary disability and quality of medical care named after E.E. Eichwald at the North-Western State Medical University named after I.I. Mechnikov of the Ministry of Health of the Russian Federation.
18A Milyutinsky lane, Moscow, 101000; 47 Piskarevsky Prospekt, Saint Petersburg, 195067.
E. D. Gordeychuk
Eurasian Association of Therapists; Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
Россия
Россия
Elizaveta D. Gordeychuk - Medical adviser of Eurasian Association of Therapists; 6th year student of the Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation.
18A Milyutinsky lane, Moscow, 101000; 1 Ostrovityanova str., Moscow, 117997.
A. N. Ermilova
Eurasian Association of Therapists; Psychiatric clinical hostpital named after P. Gannushkin
Россия
Россия
Anastasiya N. Ermilova - senior medical advisor of Eurasian Association of Therapists; psychiatrist of Psychiatric clinical hostpital named after P. Gannushkin.
18A Milyutinsky lane, Moscow, 101000; 3 Poteshnaya str., Moscow, 107076.
A. V. Klimova
Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation; Moscow City State Outpatient Hospital № 134
Россия
Россия
Anastasiya V. Klimova - PhD student of the Department of the Internal Medicine at the Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation; general practitioner at the Moscow City State Outpatient Hospital № 134.
1 Ostrovityanova str., Moscow, 117997; 24/2 Novoyasenevsky Ave., Moscow, 117574.
T. V. Kryukova
Eurasian Association of Therapists
Россия
Россия
Tamara V. Kryukova - project manager of Eurasian Association of Therapists.
18A Milyutinsky lane, Moscow, 101000.
E. S. Melnikov
Eurasian Association of Therapists; North-Western State Medical University named after I.I. Mechnikov of the Ministry of Health of the Russian Federation
Россия
Россия
Evgeny S. Melnikov - Medical adviser of Eurasian Association of Therapists; PhD student of the department of therapy, rheumatology, examination of temporary disability and quality of medical care named after E.E. Eichwald at the North-Western State Medical University named after I.I. Mechnikov of the Ministry of Health of the Russian Federation.
18A Milyutinsky lane, Moscow, 101000, Russia; 47 Piskarevsky Prospekt, Saint Petersburg, 195067.
M. A. Trubnikova
Eurasian Association of Therapists; LLC Fresenius Medical Care Kuban
Россия
Россия
Marina A. Trubnikova - Medical adviser of Eurasian Association of Therapists; nephrologist at the LLC Fresenius Medical Care Kuban;
18A Milyutinsky lane, Moscow, 101000; 48 Gorky str., Sochi, 354000.
References
1. https://www.who.int/ru/emergencies/diseases/novel-coronavirus-2019.
2. Arutyunov G. P., Tarlovskaya Ye. I., Koziolova N. A. i dr. Coordinated position of experts of the Eurasian Association of Physicians on the tactics of managing patients with comorbid pathology infected with SARS-Cov-2 // Terapevticheskiy arkhiv. 2020; 92 (9). DOI: 10.26442/00403660.2020.09.000703.
3. Arutyunov G. P., Tarlovskaya Ye. I., Arutyunov A. G., i soavt. International register «Analysis of the dynamics of comorbid diseases in patients who have undergone infection with SARS-CoV-2» (ACTIVE SARS-CoV-2): analysis of predictors of unfavorable outcomes of the acute stage of a new coronavirus infection // Rossiyskiy kardiologicheskiy zhurnal. 2021; 26 (4): 4470. https://doi.org/10.15829/1560-4071-2021-4470.
4. NICE. COVID-19 rapid guideline: managing the long-term effects of COVID-19. Available from: https://www.nice.org.uk/guidance/ng188/chapter/5-Managemen.
5. Shlyakhto Ye. V., Konradi A. O., Arutyunov G. P. i soavt. Guidelines for the diagnosis and treatment of diseases of the circulatory system in the context of the COVID-19 pandemic // Rossiyskiy kardiologicheskiy zhurnal. 2020; 25 (3): 3801. https://doi.org/10.15829/1560-4071-2020-3-3801.
6. Tadic M., Cuspidi C., Mancia G., Dell'Oro R., Grassi G. COVID-19, hypertension and cardiovascular diseases: Should we change the therapy? // Pharmacol Res. 2020; 158: 104906. DOI: 10.1016/j.phrs.2020.104906.
7. Desai A. D., Boursiquot B. C., Melki L., Wan E. Y. Management of Arrhythmias Associated with COVID-19 // Current Cardiology Reports. 2021; 2 (23). https://doi.org/10.1007/s11886-020-01434-7.
8. Vlachakis P. K., Tentolouris A., Tousoulis D., Tentolouris N. Current data on the cardiovascular effects of COVID-19 // Hellenic Journal of Cardiology. 2020; 1 (61): 46-48. https://doi.org/10.1016/j.hjc.2020.04.001.
9. Talasaz A. H., Kakavand H., Van Tassell B., Aghakouchakzadeh M., Sadeghipour P., Dunn S., Geraiely B. Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective // Cardiovascular Drugs and Therapy. 2021; 35: 249-259. https://doi.org/10.1007/s10557-020-07037-2.
10. Kochi A. N., Tagliari A. P., Forleo G. B., Fassini G. M., Tondo C. Cardiac and arrhythmic complications in patients with COVID-19 // J Cardiovasc Electrophysiol. 2020; 31 (5): 1003-1008. DOI: 10.1111/jce.14479. Epub 2020 Apr 13. PMID: 32270559; PMCID: PMC7262150.
11. Madjid M., Safavi-Naeini P., Solomon S. D., Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review // JAMA Cardiol. 2020; 5 (7): 831-840. DOI: 10.1001/jamacardio.2020.1286. PMID: 32219363.
12. Wang D., Hu B., Hu C., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China // JAMA 2020; 323: 1061. 10.1001/jama.2020.1585.
13. 13 Evans P. C., Rainger G. Ed., Mason J. C., Guzik T. J., Osto E., Stamataki Z., Neil D., Hoefer I. E., Fragiadaki M., Waltenberger J., Weber C., Bochaton-Piallat M.-L., Bäck M. Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science // Cardiovascular Research. 2020; 14 (116): 2177-2184. https://doi.org/10.1093/cvr/cvaa230.
14. Del Rio C., Collins L. F., Malani P. Long-term health consequences of COVID-19 // JAMA. 2020; 324: 1723-1724.
15. Arutyunov G. P., Tarlovskaya Ye. I., Arutyunov A. G. i dr. International register «Analysis of the dynamics of comorbid diseases in patients who have undergone infection with SARS-CoV-2 (ACTIVE SARS-CoV-2)»: methodology and design // Kardiologiya. 2020; 60 (11): 35-37. DOI: 10.18087/cardio.11.n1398.
16. Davis H. E., Assaf G. S., McCorkell L., Wei H., Low R. J., Re'em Y., Redfield S., Austin J. P., Akrami A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact // EClinicalMedicine. 2021; 38: 101019. DOI: 10.1016/j.eclinm.2021.101019. Epub 2021 Jul 15. PMID: 34308300; PMCID: PMC8280690.
17. Kamal M., Abo Omirah M., Hussein A., Saeed H. Assessment and characterisation of post-COVID-19 manifestations // Int J Clin Pract. 2021; 75 (3): e13746. DOI: 10.1111/ijcp.13746. Epub 2020 Nov 3. PMID: 32991035; PMCID: PMC7536922.
18. Xiong Q., Xu M., Li J., Liu Y., Zhang J., Xu Y., Dong W. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study // Clin Microbiol Infect. 2021; 27 (1): 89-95. DOI: 10.1016/j.cmi.2020.09.023. Epub 2020 Sep 23. PMID: 32979574; PMCID: PMC7510771.
19. Goërtz Y. M. J., Van Herck M., Delbressine J. M., Vaes A. W., Meys R., Machado F. V. C., Houben-Wilke S., Burtin C., Posthuma R., Franssen F. M. E., van Loon N., Hajian B., Spies Y., Vijlbrief H., van ’t Hul A. J., Janssen D. J. A., Spruit M. A. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? // ERJ Open Research. 2020, 6 (4) 00542-202. DOI: 10.1183/23120541.00542-2020.
20. Carfì A., Bernabei R., Landi F. Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19 // JAMA. 2020; 324 (6): 603-605. DOI: 10.1001/jama.2020.12603. PMID: 32644129; PMCID: PMC7349096.
21. Nalbandian A., Sehgal K., Gupta A., Madhavan M. V., McGroder C., Stevens J. S., Cook J. R., Nordvig A. S., Shalev D., Sehrawat T. S., Ahluwalia N., Bikdeli B., Dietz D., Der-Nigoghossian C., Liyanage-Don N., Rosner G. F., Bernstein E. J., Mohan S., Beckley A. A., Seres D. S., Choueiri T. K., Uriel N., Ausiello J. C., Accili D., Freedberg D. E., Baldwin M., Schwartz A., Brodie D., Garcia C. K., Elkind M. S. V., Connors J. M., Bilezikian J. P., Landry D. W., Wan E. Y. Post-acute COVID-19 syndrome // Nat Med. 2021; 27 (4): 601-615. DOI: 10.1038/s41591-021-01283-z. Epub 2021 Mar 22. PMID: 33753937.
22. Arutyunov A. G., Seferovich P., Bakulin I. G., i soavt. Rehabilitation after COVID-19. Resolution of the International Council of Experts of the Eurasian Association of Physicians and the Russian Cardiological Society // Rossiyskiy kardiologicheskiy zhurnal. 2021; 26 (9): 4694. DOI: 10.15829/1560-4071-2021-4694.
23. Kang Y., Chen T., Mui D., Ferrari V., Jagasia D., Scherrer-Crosbie M., Chen Y., Han Y. Cardiovascular manifestations and treatment considerations in COVID-19 // Heart. 2020; 106 (15): 1132-1141. DOI: 10.1136/heartjnl-2020-317056. Epub 2020 Apr 30. PMID: 32354800; PMCID: PMC7211105.
24. Arutyunov G. P., Tarlovskaya Ye. I., Arutyunov A. G. i dr. International register «Analysis of the dynamics of comorbid diseases in patients who have undergone SARS-CoV-2 infection» (ACTIVE SARS-CoV-2): analysis 1000 patients // Rossiyskiy kardiologicheskiy zhurnal. 2020; 25 (11): 4165. DOI: 10.15829/1560-4071-2020-4165.
25. Arutyunov G. P., Tarlovskaya Ye. I., Arutyunov A. G., i soavt. International register «Analysis of the dynamics of comorbid diseases in patients who underwent SARS-CoV-2 infection» (ACTIVE) and the register «Analysis of hospitalizations of comorbid patients infected during the second wave of SARS-CoV-2» (ACTIVE 2) // Rossiyskiy kardiologicheskiy zhurnal. 2021; 26 (3): 4358. https://doi.org/10.15829/1560-4071-2021-4358.
26. Arutyunov G. P., Tarlovskaya Ye. I., Arutyunov A. G. ot imeni gruppy soavtorov. Clinical features of the post-covid period.. Results of the international register «Analysis of the dynamics of comorbid diseases in patients who have undergone infection with SARS-CoV-2 (ACTIVE SARS-CoV-2)». Preliminary data (6 months of observation) // Rossiyskiy kardiologicheskiy zhurnal. 2021; 26 (10): 4708. DOI: 10.15829/1560-4071-2021-4708.
27. Choudry F. A., Hamshere S. M., Rathod K. S., Akhtar M. M., Archbold R. A., Guttmann O. P., Woldman S., Jain A. K., Knight C. J., Baumbach A., Mathur A., Jones D. A. High Thrombus Burden in Patients With COVID-19 Presenting With ST-Segment Elevation Myocardial Infarction // J Am Coll Cardiol. 2020; 76 (10): 1168-1176. DOI: 10.1016/j.jacc.2020.07.022. Epub 2020 Jul 14. PMID: 32679155; PMCID: PMC7833185.
28. Arutyunov A. G., Seferovich P., Bakulin I. G., i soavt. Rehabilitation after COVID-19. Resolution of the International Council of Experts of the Eurasian Association of Physicians and the Russian Cardiological Society // Rossiyskiy kardiologicheskiy zhurnal. 2021; 26 (9): 4694. DOI: 10.15829/1560-4071-2021-4694.
29. Alsagaff M. Y., Mulia E. P. B. Hypertension and COVID-19: Potential use of beta-blockers and a call for randomized evidence // Indian Heart J. 2021: S0019-4832(21)00230-3. DOI: 10.1016/j.ihj.2021.10.011. Epub ahead of print. PMID: 34717930; PMCID: PMC8550882.
30. Noveanu M., Breidthardt T., Reichlin T., Gayat E., Potocki M., Pargger H., Heise A., Meissner J., Twerenbold R., Muravitskaya N., Mebazaa A., Mueller C. Effect of oral β-blocker on short and long-term mortality in patients with acute respiratory failure: results from the BASEL-II-ICU study // Crit Care. 2010; 14 (6): R198. DOI: 10.1186/cc9317. Epub 2010 Nov 3. PMID: 21047406; PMCID: PMC3219994.
31. Natesan Vasanthakumar. Beta-Adrenergic Blockers as a Potential Treatment for COVID-19 // Patients. www.bioessays-journal.com. 20 August 2020. doi.org/10.1002/bies.202000094.
32. Heriansyah T., Nur Chomsy I., Febrianda .L, Farahiya Hadi T., Andri Wihastuti T. The Potential Benefit of Beta-Blockers for the Management of COVID-19 Protocol Therapy-Induced QT Prolongation: A Literature Review // Scientia Pharmaceutica. 2020; 88 (4): 55. https://doi.org/10.3390/ scipharm88040055.
33. Chouchana L., Beeker N., Garcelon N., Rance B., Paris N., Salamanca E., Polard E., Burgun A., Treluyer J. M., Neuraz A. AP-HP/Universities/ Inserm COVID-19 research collaboration, AP-HP Covid CDR Initiative, and «Entrepôt de Données de Santé» AP-HP Consortium». Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19 // Cardiovasc Drugs Ther. 2021 Feb 17: 1-6. DOI: 10.1007/s10557-021-07155-5. Epub ahead of print. Erratum in: Cardiovasc Drugs Ther. 2021 Mar 4; PMID: 33595761; PMCID: PMC7887412.
34. Yan F., Huang F., Xu J. et al. Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients // Cell Discov. 2020; 6: 77. https://doi.org/10.1038/s41421-020-00221-6.
35. Pinto-Sietsma S.-J., Flossdorf M., Buchholz V. R., Offerhaus J., Bleijendaal H., Beudel M., Volders P. G. A., ter Bekke R. M. A., Dormans T., Zwetsloot P.-P., de Jager P., Massberg S., Rämer P., Wendtner C., Hoffmann E., Rothe K., Feihl S., Kessler T., Pinto Y. M., Schunkert H. Antihypertensive drugs in COVID-19 infection // European Heart Journal – Cardiovascular Pharmacotherapy. 2020; 6 (6): 415-416. https://doi.org/10.1093/ehjcvp/pvaa058.
36. Oh T. K., Cho H. W., Suh J. W., Song I. A. Incidence and Mortality Associated with Cardiovascular Medication among Hypertensive COVID-19 Patients in South Korea // Yonsei Med J. 2021; 62 (7): 577-583. DOI: 10.3349/ymj.2021.62.7.577. PMID: 34164954; PMCID: PMC8236350.
37. Saifi E. S., Giorgi-Pierfranceschi M., Salvetti M., Maninetti L., Cavalli I., Muiesan M. L. Factors associated with survival in older patients affected by COVID-19: A retrospective cohort study // Arch Gerontol Geriatr. 2021; 94: 104349. DOI: 10.1016/j.archger.2021.104349. Epub 2021 Jan 21. PMID: 33508512; PMCID: PMC7825838.
38. Arutyunov G. P., Tarlovskaya Ye. I., Arutyunov A. G., Belenkov Yu. N., Konradi A. O., Lopatin Yu. M. i dr. Analysis of the effect of basic therapy drugs used to treat concomitant diseases in the period preceding infection, for the risk of death with a new coronavirus infection. Data from the international register «Analysis of the dynamics of comorbid diseases in patients who have undergone SARS-CoV-2 infection» (ACTIVE SARS-CoV-2) // Kardiologiya. 2021; 61 (9): 20-32.
39. Gao P., Wu W., Tian R., Yan X., Qian H., Guo F., Li T., Liu Z., Wang J., Zhou X., Qin Y., Zhao D., Bian X., Lin X., Zhang S. Association between tachyarrhythmia and mortality in a cohort of critically ill patients with coronavirus disease 2019 (COVID-19) // Ann Transl Med. 2021; 9 (10): 883. DOI: 10.21037/atm-21–2282. PMID: 34164517; PMCID: PMC8184440.
40. Page R. L., Joglar J. A., Caldwell M. A., Calkins H., Conti J. B., Deal B. J., Estes N. A., Field M. E., Goldberger Z. D., Hammill S. C., Indik J. H., Lindsay B. D., Olshansky B., Russo A. M., Shen W. K., Tracy C. M., Al-Khatib S. M., Evidence Review Committee Chair. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia // Circulation. 2016; 133 (14): e506-e574.
41. Calkins H. The 2019 ESC Guidelines for the Management of Patients with Supraventricular Tachycardia // Eur Heart J. 2019; 40 (47): 3812-3813. DOI: 10.1093/eurheartj/ehz837. PMID: 31837143.
42. Zhou Y., Xue S., Yang J. J. Calcium and Viruses. In: Kretsinger R. H., Uversky V. N., Permyakov E. A. (eds). Encyclopedia of Metalloproteins. Springer, New York, NY, 2013. https://doi.org/10.1007/978-1-4614-1533-6_58.
43. Zhou Y., Frey T. K., Yang J. J. Viral calciomics: interplays between Ca2+ and virus // Cell Calcium. 2009; 46 (1): 1-17. DOI: 10.1016/j.ceca.2009.05.005. Epub 2009 Jun 16. PMID: 19535138; PMCID: PMC3449087.
44. Scherbik S. V., Brinton M. A. Virus-induced Ca2+ influx extends survival of west nile virus-infected cells // J Virol. 2010; 84 (17): 8721-8731. DOI: 10.1128/JVI.00144-10. Epub 2010 Jun 10. PMID: 20538858; PMCID: PMC2918993.
45. Ueda M., Daidoji T., Du A., Yang C. S., Ibrahim M. S., Ikuta K., Nakaya T. Highly pathogenic H5N1 avian influenza virus induces extracellular Ca2+ influx, leading to apoptosis in avian cells // J Virol. 2010; 84 (6): 3068-3078. DOI: 10.1128/JVI.01923-09. Epub 2010 Jan 6. PMID: 20053741; PMCID: PMC2826054.
46. Doñate-Macián P., Jungfleisch J., Pérez-Vilaró G., Rubio-Moscardo F., Perálvarez-Marín A., Diez J., Valverde M. A. The TRPV4 channel links calcium influx to DDX3X activity and viral infectivity // Nat Commun. 2018; 9 (1): 2307. DOI: 10.1038/s41467-018-04776-7. PMID: 29899501; PMCID: PMC5998047.
47. Bai D., Fang .L, Xia S., Ke W., Wang J., Wu X., Fang P., Xiao S. Porcine deltacoronavirus (PDCoV) modulates calcium influx to favor viral replication // Virology. 2020; 539: 38-48. DOI: 10.1016/j.virol.2019.10.011. Epub 2019 Oct 22. PMID: 31670218; PMCID: PMC7112098.
48. Solaimanzadeh I. Nifedipine and Amlodipine Are Associated with Improved Mortality and Decreased Risk for Intubation and Mechanical Ventilation in Elderly Patients Hospitalized for COVID-19 // Cureus. 2020; 12 (5): e8069. DOI: 10.7759/cureus.8069. PMID: 32411566; PMCID: PMC7219014.
49. Choksi T. T., Zhang H., Chen T., Malhotra N. Outcomes of Hospitalized COVID-19 Patients Receiving Renin Angiotensin System Blockers and Calcium Channel Blockers // Am J Nephrol. 2021; 52 (3): 250-260. DOI: 10.1159/000515232. Epub 2021 Apr 7. PMID: 33827074; PMCID: PMC8089461.
50. Neuraz A., Lerner I., Digan W., Paris N., Tsopra R., Rogier A., Baudoin D., Cohen K. B., Burgun A., Garcelon N., Rance B., AP-HP/Universities/INSERM COVID-19 Research Collaboration; AP-HP COVID CDR Initiative Natural Language Processing for Rapid Response to Emergent Diseases: Case Study of Calcium Channel Blockers and Hypertension in the COVID-19 Pandemic // J Med Internet Res. 2020; 22 (8): e20773. DOI: 10.2196/20773 PMID: 32759101 PMCID: 7431235.
51. Zhang L. K., Sun Y., Zeng H. et al. Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension // Cell Discov. 2020; 6: 96. https://doi.org/10.1038/s41421-020-00235-0.
52. Peng C., Wang H., Guo Y. F., Qi G. Y., Zhang C. X., Chen T., He J., Jin Z. C. Calcium channel blockers improve prognosis of patients with coronavirus disease 2019 and hypertension // Chin Med J (Engl). 2021; 134 (13): 1602-1609. DOI: 10.1097/CM9.0000000000001479. PMID: 34133354; PMCID: PMC8280095.
53. Kow C. S., Ramachandram D. S., Hasan S. S. Clinical outcomes of hypertensive patients with COVID-19 receiving calcium channel blockers: a systematic review and meta-analysis // Hypertens Res. 2021: 1-4. DOI: 10.1038/s41440-021-00786-z. Epub ahead of print. PMID: 34754084; PMCID: PMC8576454.
54. Christiansen C. F., Pottegård A., Heide-Jørgensen U., Bodilsen J., Søgaard O. S., Maeng M., Vistisen S. T., Schmidt M., Lund L. C., Reilev M., Hallas J., Voldstedlund M., Husby A., Thomsen M. K., Johansen N. B., Brun N. C., Thomsen R. W., Bøtker H. E., Sørensen H. T. SARS-CoV-2 infection and adverse outcomes in users of ACE inhibitors and angiotensin-receptor blockers: a nationwide case-control and cohort analysis // Thorax. 2021; 76 (4): 370-379. DOI: 10.1136/thoraxjnl-2020-215768. Epub 2020 Dec 8. PMID: 33293279.
55. Yan F., Huang F., Xu J., Yang P., Qin Y., Lv J., Zhang S., Ye L., Gong M., Liu Z., Wei J., Xie T., Xu K. F., Gao G. F., Wang F. S., Cai L., Jiang C. Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients // Cell Discov. 2020; 6 (1): 77. DOI: 10.1038/s41421-020-00221-6. PMID: 33298897; PMCID: PMC7595708.
56. Lu Q. B., Jiang W. L., Zhang X., Li H. J., Zhang X. A., Zeng H. L., Du J., Yang G. L., Zhang L. K., Li R., Fang L. Q., Li H., Liu W. Comorbidities for fatal outcome among the COVID-19 patients: A hospital-based case-control study // J Infect. 2021; 82 (1): 159-198. DOI: 10.1016/j.jinf.2020.07.026. Epub 2020 Jul 27. PMID: 32731000; PMCID: PMC7384426.
57. Arutyunov G. P., Tarlovskaya Ye. I., Arutyunov A. G., Belenkov Yu. N., Konradi A. O. i soavt. Combinations of cardiovascular diseases in patients with COVID-19: impact on prognosis according to register » Analysis of the dynamics of comorbid diseases in patients who have undergone SARS-CoV-2 infection» // V pechati «Terapevticheskiy arkhiv».
Review
For citations:
Arutyunov A.G., Arutyunov G.P., Tarlovskaya E.I., Batluk T.I., Bashkinov R.A., Gordeychuk E.D., Ermilova A.N., Klimova A.V., Kryukova T.V., Melnikov E.S., Trubnikova M.A. Beta-blocker and calcium-channel blocker therapy in patients with cardiovascular pathologies during post-COVID period. Lechaschi Vrach. 2021;(12):46-54. (In Russ.) https://doi.org/10.51793/OS.2021.24.12.007
Views:
287
JATS XML
Email this article 
